Revive Therapeutics Ltd.
RVV
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.90M | -3.88M | -4.19M | -4.14M | -3.13M |
| Total Depreciation and Amortization | 100.00 | 200.00 | 300.00 | 400.00 | 400.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.78M | 1.82M | 1.84M | 1.84M | 792.90K |
| Change in Net Operating Assets | 368.70K | 150.30K | -59.60K | -137.00K | -314.10K |
| Cash from Operations | -753.50K | -1.92M | -2.41M | -2.43M | -2.65M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.20K | -22.50K | -22.50K | -500.00 | -29.70K |
| Cash from Investing | 7.20K | -22.50K | -22.50K | -500.00 | -29.70K |
| Total Debt Issued | 65.00K | -- | -- | -- | -- |
| Total Debt Repaid | -104.60K | -143.40K | -182.20K | -194.70K | -153.90K |
| Issuance of Common Stock | 84.10K | 2.10M | 2.10M | 2.10M | 2.41M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.50K | 19.30K | 58.10K | 70.60K | -241.10K |
| Cash from Financing | 16.10K | 1.47M | 1.47M | 1.47M | 1.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -730.20K | -471.00K | -964.90K | -967.70K | -1.19M |